it has actually been accepted by every person from
Drugs with combined annual sales of no less than $29 billion will lose patent protection in 2013, according to EvaluatePharma, which says more than 70% of those sales will shift to generics. The cliff is only slightly steeper than in 2012, when $27 billion of sales were lost as branded drug patents expired. The largest blockbuster set to fall off the cliff is Eli Lilly's Cymbalta for anxiety and depression (about $4.2 billion in 2011; about $3.6 billion in Q1 Q3 2012). Patent cliff losses in recent years have forced big biopharma to shift development to less profitable niche drugs targeting specific diseases, as well as consolidate, and slash costs by shrinking R and laying off 300,000 employees since 2000. "What we're going to see over the next three years is going to have to be more business model driven than budget management driven," Edmunds of Booz told GEN, adding that most senior executives he has spoken with "are getting to the place they're saying, ...